Mike Fratantoro

Researchers found that a specific fatty acid in breast milk programs immune cells to fight infections and may reduce the risk of chronic lung disease in premature infants. RT’s Three Key Takeaways: - Immune System Imprinting: Researchers discovered that t... See more

On July 1, international organizations aim to increase awareness and research for bronchiectasis to improve patient outcomes and healthcare access. RT’s Three Key Takeaways: - Global Awareness Initiative: The Forum of International Respiratory Societies (... See more

ENA Respiratory’s INNA-051 non-vaccine, intranasal spray is designed to boost immune defenses and reduce illness from respiratory viruses. A new clinical trial led by researchers at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccin... See more

Journavx is an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. RT’s Three Key Takeaways - The FDA has approved Journavx (suzetrigine) 50 mg, a first-in-class non-opioid analge... See more

This story was originally published on ProPublica, a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story newsletter to receive stories like this one in your inbox. “Not Just Measles”: Whooping Cough Cases Are Soaring as Vaccine Rates ... See more